Head to Head Analysis: Allurion Technologies (NYSE:ALUR) vs. Haleon (NYSE:HLN)

Allurion Technologies (NYSE:ALUR) and Haleon (NYSE:HLN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares Allurion Technologies and Haleon’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Allurion Technologies	-158.30%	N/A	-59.91%
Haleon	N/A	N/A	N/A

Earnings and Valuation

This table compares Allurion Technologies and Haleon”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allurion Technologies	$32.11 million	0.42	-$7.20 million	($12.53)	-0.14
Haleon	$11.02 billion	3.88	$1.84 billion	$0.39	24.59

Haleon has higher revenue and earnings than Allurion Technologies. Allurion Technologies is trading at a lower price-to-earnings ratio than Haleon, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Allurion Technologies has a beta of -0.46, indicating that its stock price is 146% less volatile than the S&P 500. Comparatively, Haleon has a beta of 0.2, indicating that its stock price is 80% less volatile than the S&P 500.

Institutional and Insider Ownership

21.4% of Allurion Technologies shares are owned by institutional investors. Comparatively, 6.7% of Haleon shares are owned by institutional investors. 9.6% of Allurion Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Allurion Technologies and Haleon, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allurion Technologies	1	2	1	0	2.00
Haleon	0	6	3	1	2.50

Allurion Technologies presently has a consensus price target of $9.25, suggesting a potential upside of 431.61%. Haleon has a consensus price target of $12.33, suggesting a potential upside of 28.52%. Given Allurion Technologies’ higher probable upside, equities research analysts clearly believe Allurion Technologies is more favorable than Haleon.

Summary

Haleon beats Allurion Technologies on 11 of the 14 factors compared between the two stocks.

About Allurion Technologies

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.